Full history for every metric is available with a Kvantra account

Stock profile
Bio-Techne Corporation logo

Bio-Techne Corporation (TECH)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
66.1
History
P/E NTM
33.4
Market cap
11.42B
Currency USD
KvantraRankAbout42
IValue22
IIQuality66
IIIMomentum42
Current price
72.67 USD-0.04%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
2020202120222023202420252026TTM
Total revenue$m7399311,1061,1371,1591,2201,2151,228
Operating profit$m252241
Net profit$m22914027228516873182172
EPS reported$1.161.10
Operating cashflow per share$1.872.15
Capex per share$0.180.19
FCF per share$1.691.97
Free cash flow$m263308
Net debt$m24.4-65.6
Book value equity$m2,1082,166
Book value per share$13.4313.71
Number of sharesm157.01157.93
DPS (TTM paid)$0.400.40

Financial summary

Financials in USD
2020202120222023202420252026TTM
Value
P/E TTMx60.9166.06
P/B LTMx5.235.27
P/S LTMx9.079.29
P/FCF LTMx41.8637.04
EV/EBITDA LTMx32.1534.52
EV/Sales LTMx9.099.24
Earnings Yield LTM%1.64%1.51%
FCF Yield%2.39%2.70%
Quality
ROE%8.63%8.22%
ROIC%7.81%7.31%
Operating margin%20.73%19.61%
Gross margin%65.77%65.75%
FCF/Sales%21.66%25.09%
Growth and momentum
EPS Growth YoY%+152.17%+124.49%
Sales Growth YoY%-0.38%+0.94%
Net Income Growth YoY%+147.77%+120.52%
FCF Growth%+2.60%+37.55%
Operating Profit Growth%+146.34%+119.09%
Dividend and capital structure
Dividend Yield%0.45%0.55%
Dividend Growth%+25.00%-
Payout Ratio%27.41%28.93%
FCF/Debtx0.911.08
Net Debt/EBITDAx0.07-0.20
EBIT/Net interestx46.6051.89
Net debt/market cap%0.22%-0.57%
Net debt/Equityx0.01-0.03
Gross debt/equityx0.140.13

ETFs that hold Bio-Techne

FundTickerPosition#Weight
Invesco RAFI US 1500 Small-Mid ETFPRFZ100.34%
NYLI Merger Arbitrage ETFMNA43.47%
Global X Genomics & Biotechnology UCITS ETFGN0M.DE93.78%
Global X - Genomics & Biotechnology ETFGNOM103.66%
AltShares Merger Arbitrage ETFARB42.49%

Funds with Bio-Techne among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price72.67 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Bio-Techne Corporation (TECH)

TECH · NASDAQ · Healthcare
72.67 USD-0.04%
Sign up to track this stock
Benchmarks
KvantraRank42
Market cap11.42B
P/E NTM33.4
P/E TTM66.1
KvantraRank?42 / 100
Value
22
Quality
66
Momentum
42
Financialsin USD
20252026TTM
ETFs that hold Bio-Techne
FundTickerPosition#Weight
Invesco RAFI US 1500 Small-Mid ETFPRFZ100.34%
NYLI Merger Arbitrage ETFMNA43.47%
Global X Genomics & Biotechnology UCITS ETFGN0M.DE93.78%
Global X - Genomics & Biotechnology ETFGNOM103.66%
AltShares Merger Arbitrage ETFARB42.49%

Funds with Bio-Techne among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current72.67 USD
Upside
Price consensus
Last year average price target
Current price72.67 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free